GSK And Novartis Double Down On Neglected Disease R&D Spend
Big Pharma Steps Up
GSK will invest over $1bn over the next decade to develop medicines that combat malaria, neglected tropical diseases and antibiotic resistance, while Novartis is putting in $250m over the next five years.
